Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (Unknown)
- New search for: McNamara, Blair
- New search for: Chang, Yifan
- New search for: Mutlu, Levent
- New search for: Harold, Justin
- New search for: Santin, Alessandro D
- New search for: McNamara, Blair
- New search for: Chang, Yifan
- New search for: Mutlu, Levent
- New search for: Harold, Justin
- New search for: Santin, Alessandro D
In:
Expert Opinion on Biological Therapy
;
23
, 3
;
227-233
;
2023
- Article (Journal) / Electronic Resource
-
Title:Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer
-
Contributors:McNamara, Blair ( author ) / Chang, Yifan ( author ) / Mutlu, Levent ( author ) / Harold, Justin ( author ) / Santin, Alessandro D ( author )
-
Published in:Expert Opinion on Biological Therapy ; 23, 3 ; 227-233
-
Publisher:
- New search for: Taylor & Francis
-
Publication date:2023-03-04
-
Size:7 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:Unknown
-
Keywords:
-
Source:
Table of contents – Volume 23, Issue 3
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 223
-
Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS)Leclercq-cohen, Gabrielle / Bacac, Marina / Klein, Christian et al. | 2023
- 227
-
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancerMcNamara, Blair / Chang, Yifan / Mutlu, Levent / Harold, Justin / Santin, Alessandro D et al. | 2023
- 235
-
Ravulizumab for the treatment of myasthenia gravisVanoli, Fiammetta / Mantegazza, Renato et al. | 2023
- 243
-
Belimumab for the treatment of pediatric patients with lupus nephritisStohl, William / Kwok, Alyssa et al. | 2023
- 253
-
Biological therapies for myasthenia gravisUzawa, Akiyuki / Utsugisawa, Kimiaki et al. | 2023
- 261
-
Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancerRocco, Danilo / Della Gravara, Luigi / Battiloro, Ciro / Palazzolo, Giovanni / Gridelli, Cesare et al. | 2023
- 269
-
Oncolytic virus therapy for malignant gliomas: entering the new eraFudaba, Hirotaka / Wakimoto, Hiroaki et al. | 2023
- 283
-
Gene therapy for alpha-1 antitrypsin deficiency: an updatePires Ferreira, Debora / Gruntman, Alisha M / Flotte, Terence R et al. | 2023
- 293
-
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter studyMocci, Giammarco / Tursi, Antonio / Maconi, Giovanni / Cataletti, Giovanni / Mantia, Beatrice / Serio, Mariaelena / Scarcelli, Antonella / Pagnini, Cristiano / Graziani, Maria Giovanna / Di Paolo, Maria Carla et al. | 2023
- 305
-
Withdrawal of biologic therapy in juvenile idiopathic arthritis due to remission: predictors of flare and outcomesTanatar, Ayşe / Akgün, Özlem / Çağlayan, Şengül / Bağlan, Esra / Otar Yener, Gülçin / Öztürk, Kübra / Çakan, Mustafa / Sönmez, Hafize Emine / Sözeri, Betül / Aktay Ayaz, Nuray et al. | 2023